Bristol-Myers Squibb Co
BMY:NYSE
| Last | Change / % Change | Dividend Yield | Volume | Avg Volume (10 day) |
| 43.30 | 0.53 1.24% | 3.27% | 11,130,086 | 13.2M |
Recent News Headlines for Bristol-Myers Squibb Co
- Bristol-Myers Squibb Announces Intention to Voluntarily Delist Preferred Stock
NEW YORK--(BUSINESS WIRE)--May 16, 2013-- Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has notified the New York Stock Exchange ("NYSE") of its intention to voluntarily delist its $2 Convertible Preferred Stock (the "Preferred Stock") from the NYSE.
- Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
NEW YORK--(BUSINESS WIRE)--May 15, 2013-- Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference at 7 p.m. EDT (6 p.m. CDT) on Sunday, June 2, 2013, to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting, with a focus on the immuno-oncology portfolio, and address inquiries from investors and analysts.
- Bristol-Myers Squibb Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting
-- Data on Yervoy(R) (ipilimumab) and the investigational PD-1 receptor blocking antibody nivolumab, to be highlighted in six oral presentations and featured in ASCO press briefings
- Bristol-Myers Squibb Advances Leadership Position -2-
Immune-mediated Dermatitis: -- In the pivotal Phase 3 study in YERVOY-treated patients, severe, life-threatening or fatal immune-mediated dermatitis (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated
- Bristol-Myers Squibb Advances Leadership Position -3-
infusion reactions Cardiopulmonary Arrest -- Cardiopulmonary arrest and/or sudden death occurred in 4 (2%) of 208 patients with squamous cell carcinoma of the head and neck treated with